FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroGen (NASDAQ: FGEN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025, in New York. CEO Thane Wettig will present on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel.
The presentation will be available via live webcast, and the management team will conduct one-on-one meetings with investors during the conference. A replay will be accessible on FibroGen's website in the Investors and Media section for 90 days following the event.
FibroGen (NASDAQ: FGEN) ha annunciato la sua partecipazione al 27¡ã H.C. Wainwright Annual Global Investment Conference, che si terr¨¤ dall'8 al 10 settembre 2025 a New York. Il CEO Thane Wettig terr¨¤ una presentazione marted¨¬ 9 settembre alle 12:00 ET presso il Lotte New York Palace Hotel.
La presentazione sar¨¤ trasmessa in diretta via webcast e il team di gestione terr¨¤ incontri individuali con gli investitori durante la conferenza. Una registrazione sar¨¤ disponibile nella sezione Investors and Media del sito web di FibroGen per 90 giorni dopo l'evento.
FibroGen (NASDAQ: FGEN) anunci¨® su participaci¨®n en la 27.? conferencia anual global de inversi¨®n H.C. Wainwright, que se celebrar¨¢ del 8 al 10 de septiembre de 2025 en Nueva York. El CEO Thane Wettig presentar¨¢ el martes 9 de septiembre a las 12:00 p.m. ET en el Lotte New York Palace Hotel.
La presentaci¨®n se transmitir¨¢ en directo por webcast y el equipo directivo mantendr¨¢ reuniones individuales con inversores durante la conferencia. Una grabaci¨®n estar¨¢ disponible en la secci¨®n Investors and Media del sitio web de FibroGen durante 90 d¨ªas despu¨¦s del evento.
FibroGen (NASDAQ: FGEN)?(?) 2025? 9? 8??? 10??? ???? ??? H.C. Wainwright ?27? ?? ??? ?? ????? ????? ??????. CEO Thane Wettig? 9? 9? ??? ?????(ET) ?? ?? 12:00? Lotte New York Palace Hotel?? ??? ?????.
??? ??? ????? ????, ???? ???? ?? ?? ????? ??? ??? ?????. ?? ??? ?? ?? ? 90? ?? FibroGen ????? Investors and Media ???? ??? ? ????.
FibroGen (NASDAQ: FGEN) a annonc¨¦ sa participation ¨¤ la 27e conf¨¦rence annuelle mondiale d'investissement H.C. Wainwright, qui se tiendra du 8 au 10 septembre 2025 ¨¤ New York. Le PDG Thane Wettig fera une pr¨¦sentation le mardi 9 septembre ¨¤ 12h00 ET au Lotte New York Palace Hotel.
La pr¨¦sentation sera diffus¨¦e en direct via webcast et l'¨¦quipe de direction m¨¨nera des r¨¦unions individuelles avec des investisseurs pendant la conf¨¦rence. Une rediffusion sera accessible sur le site web de FibroGen, dans la rubrique Investors and Media, pendant 90 jours suivant l'¨¦v¨¦nement.
FibroGen (NASDAQ: FGEN) gab seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference bekannt, die vom 8. bis 10. September 2025 in New York stattfindet. CEO Thane Wettig wird am Dienstag, den 9. September, um 12:00 Uhr ET im Lotte New York Palace Hotel sprechen.
Die Pr?sentation wird per Live-Webcast ¨¹bertragen und das Managementteam f¨¹hrt w?hrend der Konferenz Einzelgespr?che mit Investoren. Eine Aufzeichnung wird auf der FibroGen-Website in der Rubrik Investors and Media f¨¹r 90 Tage nach der Veranstaltung verf¨¹gbar sein.
- None.
- None.
SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc.?(NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th?Annual?Global Investment Conference?being held?September 8-10, 2025,?in?New York, NY.
Thane Wettig, Chief Executive Officer of?FibroGen, will deliver a company presentation on?Tuesday, September 9?at?12:00 PM ET?at the?Lotte New York Palace Hotel. A live webcast of the presentation will be available?.
FibroGen¡¯s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to the?FibroGen?website on the??page of the Investors and Media section for 90 days.
About?FibroGen
FibroGen, Inc.?is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (°®Èð׿?, EVRENZO?) is currently approved in?China,?Europe,?Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the?U.S.?FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit?.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
FAQ
When is FibroGen (FGEN) presenting at the H.C. Wainwright Conference 2025?
How can investors access FibroGen's H.C. Wainwright Conference presentation?
Can investors meet with FibroGen's management at the H.C. Wainwright Conference?
Where will the H.C. Wainwright Conference 2025 be held?
